| Generic name | Tagraxofusp-erzs |
| Brand name(s), other common name(s) | ElzonrisTM |
| Drug type | CD123-directed cytotoxin |
| How the drug is given | Intravenous |
Indications and Usage
Tagraxofusp-erzs is FDA approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older.
Side effects needing medical attention
The most common adverse reactions are capillary leak syndrome (CLS), nausea, fatigue, peripheral edema, fever, and weight increase.
Capillary leak syndrome (CLS), which may be life-threatening or fatal, can occur in patients receiving tagraxofusp-erzs. Physicians are advised to monitor for signs and symptoms of CLS and take actions as recommended in the full prescribing information.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.